METHOD OF ADMINISTRATION AND TREATMENT

• US 20190365798A1
• Filed: 08/20/2019
• Published: 12/05/2019
• Est. Priority Date: 09/15/2017
• Status: Active Grant

• Current Assignee: Dyve Biosciences, Inc.
• Original Assignee: Ampersand Biopharmaceuticals Inc.
• Inventors: Beal, Ryan
• Granted Patent: US 10,639,326 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/045 Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
• CPC Class Codes: A61K 31/133 having hydroxy groups, e.g. sphingosine
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/4172 Imidazole-alkanecarboxylic acids, e.g. histidine
• CPC Class Codes: A61K 31/661 Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
• CPC Class Codes: A61K 31/685 one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 33/30 Zinc; Compounds thereof
• CPC Class Codes: A61K 33/42 Phosphorus; Compounds thereof
• CPC Class Codes: A61K 35/00 Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/12 Carboxylic acids; Salts or anhydrides thereof
• CPC Class Codes: A61K 47/14 Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• CPC Class Codes: A61K 47/183 Amino acids, e.g. glycine, EDTA or aspartame
• CPC Class Codes: A61K 47/22 Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• CPC Class Codes: A61K 47/24 : containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• CPC Class Codes: A61K 9/0014 : Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/06 : Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61K 9/16 : Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51
• CPC Class Codes: A61K 9/7023 : Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006
• CPC Class Codes: A61P 35/04 : specific for metastasis
• CPC Class Codes: C07K 16/2818 : against CD28 or CD152
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid tumors. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described herein.

Claims

1. A method of treating a gout, comprising administering a transdermal formulation containing a buffering agent to a patient suffering from a gout.

2. The method of claim 1, wherein the transdermal dermal formulation is administered to a patient topically.

3. The method of claim 1, wherein, the transdermal formulation is effective in reducing the symptoms of a patient suffering from gout.

4. The method of claim 1, wherein the transdermal formulation raises the pH in the vicinity of where the patient is suffering from gout.

5. The method of claim 1, wherein the transdermal formulation reduces the level of uric acid in the blood.

6. The method of claim 1, wherein the transdermal formulation reduces the level of uric acid at the site where the patient is suffering from gout.

7. The method of claim 6, wherein the transdermal formulation reduces the presence of uric acid crystals at the site where the patient is suffering from gout.

8. The method of claim 1, wherein the transdermal formulation reduces the effects of diseases resultant from gout.

9. The method of claim 8, wherein the disease is osteoarthritis, rheumatoid arthritis or psoriatic arthritis.

10. The method of claim 1, wherein a buffering agent is one or more buffering agents.

11. The method of claim 1, wherein the buffering agent is sodium bicarbonate

12. The method of claim 11, wherein the sodium bicarbonate is at a concentration from about 30% to 35% w/w of the transdermal formulation.

13. The method of claim 11, wherein the sodium bicarbonate is at a concentration of 33% w/w of the transdermal formulation.

14. The method of claim 1, wherein a gout is one or more of a recurrent gout attack, gouty arthritis, hyperuricaemia, gout related cardiovascular disorders (e.g. hypertension, cardiovascular disease, coronary heart disease), Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, inflammatory joint disease, arthritis, osteoarthritis, rheumatoid arthritis and psoriatic arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis or sarcoidosis.

15. The method of claim 1, wherein the transdermal formulation also includes one or more other therapeutic agents.

16. The method of claim 15, wherein the one or more other therapeutic agents are an anti-inflammatory, colchicine, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDS), oral urate-lowering therapy, menthol, a xanthine oxidase inhibitor, allopurinol, febuxostat, lesinurad, pegloticase or probenecid.

17. The method of claim 1, wherein the buffering agent comprises a carbonate salt, lysine, tris, a phosphate buffer and/or 2-imidazole-1-yl-3-ethoxycarbonylpropionic acid (IEPA), or a combination thereof.

18. The method of claim 17, wherein the buffering agent constitutes between 10% -56% w/w of the transdermal formulation.

19. The method of claim 1, wherein a buffering agent penetrates the skin of the patient.

20. The method of claim 1, wherein the transdermal formulation comprises a buffering agent in an amount between about 10% -45% w/w;

a penetrant portion in an amount between about 5% -55% w/w;

a detergent portion in an amount between about 1% to 15% w/w; and

water in an amount between about 15% to 65% w/w.